Achieve Life Sciences, Inc. Interest Expense Nonoperating
Achieve Life Sciences, Inc. (ACHV) reported Interest Expense Nonoperating of $277.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-08-11
- Achieve Life Sciences, Inc. interest expense nonoperating for the quarter ending 2026-06-30 was $277.00K, a 45.03% increase year-over-year.
- Achieve Life Sciences, Inc. interest expense nonoperating for the quarter ending 2026-03-31 was $274.00K, a 48.11% increase year-over-year.
- Achieve Life Sciences, Inc. interest expense nonoperating for the quarter ending 2025-12-31 was $251.00K, a 27.41% increase year-over-year.
- Achieve Life Sciences, Inc. interest expense nonoperating for the quarter ending 2025-09-30 was $192.00K, a 47.54% decline year-over-year.
- Achieve Life Sciences, Inc. interest expense nonoperating for fiscal 2025 was $819.00K, a 62.43% decline from fiscal 2024.
- Achieve Life Sciences, Inc. interest expense nonoperating for fiscal 2024 was $2.18M, a 23.59% decline from fiscal 2023.
- Achieve Life Sciences, Inc. interest expense nonoperating for fiscal 2023 was $2.85M, a 59.47% increase from fiscal 2022.
- Achieve Life Sciences, Inc. interest expense nonoperating for fiscal 2022 was $1.79M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $277.00K 10-Q · filed 2026-08-11 | $551.00K 10-Q · filed 2026-08-11 | $802.00K derived: sum of 3 quarters · filed 2026-08-11 | $994.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $274.00K 10-Q · filed 2026-05-12 | $525.00K derived: sum of 2 quarters · filed 2026-05-12 | $717.00K derived: sum of 3 quarters · filed 2026-05-12 | $908.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $251.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $443.00K derived: sum of 2 quarters · filed 2026-03-24 | $634.00K derived: sum of 3 quarters · filed 2026-08-11 | $819.00K 10-K · filed 2026-03-24 |
| 2025-09-30 | $192.00K 10-Q · filed 2025-11-06 | $383.00K derived: sum of 2 quarters · filed 2026-08-11 | $568.00K 10-Q · filed 2025-11-06 | $765.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $191.00K 10-Q · filed 2026-08-11 | $376.00K 10-Q · filed 2026-08-11 | $573.00K derived: sum of 3 quarters · filed 2026-08-11 | $939.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $185.00K 10-Q · filed 2026-05-12 | $382.00K derived: sum of 2 quarters · filed 2026-05-12 | $748.00K derived: sum of 3 quarters · filed 2026-05-12 | $1.55M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $197.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $563.00K derived: sum of 2 quarters · filed 2026-03-24 | $1.37M derived: sum of 3 quarters · filed 2026-03-24 | $2.18M 10-K · filed 2026-03-24 |
| 2024-09-30 | $366.00K 10-Q · filed 2025-11-06 | $1.17M derived: sum of 2 quarters · filed 2025-11-06 | $1.98M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $804.00K 10-Q · filed 2025-08-07 | $1.62M 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $813.00K 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | $2.85M 10-K · filed 2026-03-24 | |||
| 2022-12-31 | $1.79M 10-K · filed 2025-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |